EU approves Eisai's breast cancer drug Halaven

03/24/2011 | InPharm.com

European regulators approved Eisai's injectable drug Halaven to treat certain breast cancer patients who have received at least two chemotherapy regimens. The treatment is based on a sea sponge that is thought to inhibit growth of cancer cells.

View Full Article in:

InPharm.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI